BANB:SWX
BACHEM HOLDING AG
CHFÂ 73.65
arrow_upward
+1.24%(+0.90) 1D
Aug 7, 5:30:53 PM GMT+2 · CHF
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BANB...
Open
CHFÂ 72.60
High
CHFÂ 75.05
Low
CHFÂ 72.60
Mkt. cap
5.52B
Avg. vol.
129.86K
Volume
99.11K
Dividend
1.22%
Quarterly dividend
CHFÂ 0.22
Ex-dividend date
May 4, 2026
P/E ratio
37.13
52-wk high
CHFÂ 83.25
52-wk low
CHFÂ 48.52
EPS
CHFÂ 1.98
Shares outstanding
75.00M
No. of employees
3K
Open
CHFÂ 72.60
High
CHFÂ 75.05
Low
CHFÂ 72.60
Mkt. cap
5.52B
Avg. vol.
129.86K
Volume
99.11K
Dividend
1.22%
Quarterly dividend
CHFÂ 0.22
Ex-dividend date
May 4, 2026
P/E ratio
37.13
52-wk high
CHFÂ 83.25
52-wk low
CHFÂ 48.52
EPS
CHFÂ 1.98
Shares outstanding
75.00M
No. of employees
3K
Profile
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
About BACHEM HOLDING AG
AI content may include mistakes. Learn more